CVRx, Inc., a commercial-stage medical device company, develops, manufactures, and commercializes neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction, also known as systolic heart failure. It sells its products through a direct sales force, as well as sales agents and independent distributors in the United States, Germany, the rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Symbol | CVRX |
|---|---|
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical - Devices |
| CEO | Kevin Hykes |
| Employees | 206 |
| Headquarters | Minneapolis, MN, US |
| IPO | 2021-06-30 |
| Website | www.cvrx.com |